Overview

Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury

Status:
Completed
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy of an infusion of Ronopterin (VAS203) on clinical outcome in patients with moderate and severe traumatic brain injury. Half of the participants will receive Ronopterin (VAS203), while the other half will receive placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Vasopharm GmbH
Collaborator:
ICON plc